SCHEMBL29464056

SCHEMBL29464056

N=C(N)NCCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 11/20 0.49
▸ NPY1R P25929 6/20 0.49
▸ NPY2R P49146 4/20 0.49
▸ NPY5R Q15761 4/20 0.49
▸ C5AR1 P21730 1/20 0.42
▸ FNTA P49354 3/20 0.42
▸ FNTB P49356 3/20 0.42
▸ PGGT1B P53609 3/20 0.42
▸ GNPAT O15228 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31252942 1.00 NPY4R (0.49) NPY4RNPY1RNPY2RNPY5RC5AR1
SCHEMBL30449937 0.95 NPY4R (0.56) NPY4RNPY1RNPY2RNPY5R
SCHEMBL38660264 0.94 NPY4R (0.46) NPY4RNPY1RNPY2RNPY5RC5AR1
SCHEMBL31453827 0.94 NPY4R (0.46) NPY4RNPY1RNPY2RNPY5RC5AR1
SCHEMBL29420164 0.93 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RC5AR1
SCHEMBL30152128 0.93 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RC5AR1
SCHEMBL29461968 0.93 NPY4R (0.46) NPY4RNPY1RNPY2RNPY5RFNTA
SCHEMBL17887897 0.93 NPY4R (0.61) NPY4RNPY1RNPY2RNPY5R
SCHEMBL17887995 0.93 NPY4R (0.61) NPY4RNPY1RNPY2RNPY5R
SCHEMBL30676227 0.93 NPY4R (0.46) NPY4RNPY1RNPY2RNPY5RC5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296935-A1 Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase CELLTAXIS LLC (US) 2025-09-25 — — US disclosed
US-12173009-B2 Diamine derivatives as inhibitors of leukotriene A4 hydrolase CELLTAXIS, LLC (US) 2024-12-24 — — US disclosed
US-20230250104-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE CELLTAXIS LLC (US) 2023-08-10 — — US disclosed
US-11267819-B2 Diamine derivatives as inhibitors of leukotriene A4 hydrolase Celltaxsis, LLC (US) 2022-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12173009-B2 Diamine derivatives as inhibitors of leukotriene A4 hydrolase LTA4H, LTB4R, LTC4S NPY4R 266/4885NPY1R 387/4885NPY2R 772/4885
US-20250296935-A1 Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase LTA4H, LTB4R, LTC4S NPY4R 266/4885NPY1R 387/4885NPY2R 772/4885
US-11267819-B2 Diamine derivatives as inhibitors of leukotriene A4 hydrolase LTA4H, LTB4R, LTC4S NPY4R 266/4885NPY1R 387/4885NPY2R 772/4885
US-20230250104-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE LTA4H, LTB4R, LTC4S NPY4R 266/4885NPY1R 387/4885NPY2R 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback